The aim of this study was to compare the risk of all grades and high grades (grades 3 and 4) hepatotoxicity associated with 4 new-generation BCR-ABL TKIs (bosutinib, dasatinib, nilotinib, and ponatinib) vs the first generation BCR-ABL TKI imatinib in patients with CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.